美国国立癌症研究所抗肿瘤药物筛选数据库在评估毒物兴奋效应方面的局限性。 - Suppr | 超能文献

Limitations in the National Cancer Institute antitumor drug screening database for evaluating hormesis.

作者信息

Crump Kenny S

出版信息

Toxicol Sci. 2007 Aug;98(2):599-601; author reply 602-3. doi: 10.1093/toxsci/kfm135. Epub 2007 May 29.

DOI:10.1093/toxsci/kfm135

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Limitations in the National Cancer Institute antitumor drug screening database for evaluating hormesis.美国国立癌症研究所抗肿瘤药物筛选数据库在评估毒物兴奋效应方面的局限性。

Toxicol Sci. 2007 Aug;98(2):599-601; author reply 602-3. doi: 10.1093/toxsci/kfm135. Epub 2007 May 29.

2

Hormesis outperforms threshold model in National Cancer Institute antitumor drug screening database.在国立癌症研究所抗肿瘤药物筛选数据库中，兴奋效应优于阈值模型。

Toxicol Sci. 2006 Dec;94(2):368-78. doi: 10.1093/toxsci/kfl098. Epub 2006 Sep 1.

3

Hormesis gets massive data support.

Environ Sci Technol. 2006 Nov 1;40(21):6525-6.

4

[Antitumor drug screening at the National Cancer Institute, U.S.A].[美国国立癌症研究所的抗肿瘤药物筛选]

Gan To Kagaku Ryoho. 1987 Oct;14(10):2809-15.

5

Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.在美国国立癌症研究所的抗癌筛选中，针对化学结构、靶点特异性和作用机制对体外和体内活性进行评估。

J Med Chem. 2006 Mar 23;49(6):1964-79. doi: 10.1021/jm051029m.

6

The role of the National Cancer Institute in drug development.美国国立癌症研究所在药物研发中的作用。

Clin Adv Hematol Oncol. 2005 Apr;3(4):257-8.

7

Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program.美国国立癌症研究所药物筛选计划人类细胞系中的谷胱甘肽相关酶。

Mol Pharmacol. 1996 Jul;50(1):149-59.

8

Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.将通路基因表达与美国国立癌症研究所抗癌筛选的生长抑制反应及药物作用机制联系起来。

Pharmacogenomics J. 2005;5(6):381-99. doi: 10.1038/sj.tpj.6500331.

9

Drug development and hormesis: changing conceptual understanding of the dose response creates new challenges and opportunities for more effective drugs.

Curr Opin Drug Discov Devel. 2006 Jan;9(1):117-23.

10

Some thoughts on the reporting of adverse events in phase II cancer clinical trials.关于癌症II期临床试验中不良事件报告的一些思考。

J Clin Oncol. 2006 Aug 20;24(24):3821-2. doi: 10.1200/JCO.2006.06.9856.

引用本文的文献

1

Hormesis: a brief reply to an advocate.毒物兴奋效应：给一位倡导者的简短回复。

Environ Health Perspect. 2010 Apr;118(4):A153; author reply A153-4. doi: 10.1289/ehp.0901681.

2

Hormesis: a conversation with a critic.毒物兴奋效应：与一位批评者的对话。

Environ Health Perspect. 2009 Sep;117(9):1339-43. doi: 10.1289/ehp.0901002. Epub 2009 Jun 9.

3

Ad hoc and fast forward: the science of hormesis growth and development.特设与快速推进： hormesis 生长与发育的科学

Environ Health Perspect. 2009 Sep;117(9):1333-8. doi: 10.1289/ehp.0900761. Epub 2009 May 20.